Chinese guidelines for the rehabilitation treatment of knee osteoarthritis: An CSPMR evidence‐based practice guideline

Abstract

BackgroundKnee osteoarthritis (KOA) is the most common degenerative joint disease in China, causing a huge economic burden on patients, families, and society. Standardized KOA rehabilitation treatment is an important means to prevent and treat the disease and promote the development of high‐quality medical services. This guideline is updated on the basis of the 2016 and 2019 editions.MethodsClinical questions regarding rehabilitation assessment and treatment were selected through clinical questions screening and deconstruction, and multiple rounds of Delphi questionnaire consultation. The International Classification of Functioning, Disability and Health (ICF) was used as the theoretical framework, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method was used to grade the quality of evidence and recommendations.ResultsThe reporting of this guideline followed the standard of Reporting Items for Practice Guidelines in Healthcare (RIGHT). Taking into account patients' preferences and values and the needs of Chinese clinical practice, a total of 11 clinical questions and 28 recommendations were established. The clinical questions were grouped into two categories: KOA assessment (body function, body structure, activity and participation, quality of life, and environmental factors and clinical outcomes assessment, resulting in 9 recommendations) and KOA treatment (health education, therapeutic exercise, therapeutic modalities, occupational therapy, assistive devices, and regenerative rehabilitation approaches, resulting in 19 recommendations).ConclusionThis is the first evidence‐based guideline for KOA rehabilitation in China utilizing the ICF framework. This guideline provides key guidance for developing systematic, standardized, and precise rehabilitation protocols for KOA across various healthcare settings.

Barriers to and facilitators of living guidelines use in low-income and middle-income countries: a scoping review

“…The remaining two studies, from Chile and Lebanon, described the establishment of living guidelines. Among the four China-based studies, one reported the medications used to treat mild to moderate COVID-19 illness,42 one described the development of living Chinese medicine guidelines for treating COVID-19 patients,43 one covered a broad appraisal of the development of the living guidelines,37 and one looked at the development of a proposal for living, evidence-based guidelines on the integration of conventional Chinese medicine and Western medicine 39. The study from Lebanon showed how a framework for developing living recommendations for healthcare was produced, and the study from Chile emphasised the significance of thresholds for developing the living recommendations that are defined for the treatment of COVID-19 40…”